Form 4: Marimed CEO Levine Converts RSUs, Adjusts Holdings

Marimed Inc.'s President and CEO, Jon R. Levine, converted Restricted Stock Units into common stock and sold shares to cover tax obligations.

Summary

• Jon R. Levine, President and CEO, Director, and 10% Owner of Marimed Inc., reported changes in his beneficial ownership.
• On September 7, 2025, Levine acquired 23,334 shares of common stock through the conversion of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 6,849 shares of common stock were disposed of to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.1555 per share.
• Following these transactions, Levine directly owns 20,783,748 shares of common stock.
• An additional 6,684,640 shares are indirectly held by the Jon Levine Family Trust, for which Levine disclaims beneficial ownership for Section 16 purposes.
• Levine also holds 23,333 remaining Restricted Stock Units, which were granted on March 7, 2023, and are scheduled to vest on March 7, 2026.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing (Form 4) detailing the conversion of restricted stock units and subsequent tax-related share disposition. It does not inherently indicate positive or negative sentiment about the company's performance or future prospects, but rather reflects a planned compensation event.

Positives

• The conversion of Restricted Stock Units (RSUs) indicates a vesting event, which is a planned component of executive compensation.
• The acquisition of shares through RSU conversion increases direct ownership, aligning executive interests with shareholders, although partially offset by tax-related sales.

Negatives

• A portion of shares (6,849) was sold to cover tax liabilities, which is a common practice but results in a reduction of direct holdings.

Future Outlook

Remaining Restricted Stock Units (RSUs) granted on March 7, 2023, are scheduled to vest on March 7, 2026, indicating future equity compensation events.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities [held by the Jon Levine Family Trust], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies. It reflects standard equity compensation practices where executives convert vested restricted stock units into common shares, often selling a portion to cover tax liabilities. It does not provide specific industry-related insights beyond the company's internal compensation structure.

Comparison to Industry Standards

• The RSU conversion and subsequent sale for tax withholding are standard practices for executive compensation in publicly traded companies.
• There are no specific comparable companies or projects mentioned in this filing to provide a detailed comparative analysis.
• The transaction price of $0.1555 for tax withholding shares is specific to Marimed's stock value at the time of the transaction.

Related Party Transactions

• Indirect ownership of 6,684,640 common stock shares by the Jon Levine Family Trust, for which the reporting person disclaims beneficial ownership for Section 16 purposes.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion (already accounted for in outstanding shares), but also a signal of executive compensation structure.
• Management: Jon R. Levine's compensation structure includes equity, aligning his interests with shareholders.

Next Steps

• Vesting of remaining 23,333 Restricted Stock Units on March 7, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the conversion of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are standard components of executive compensation and do not typically provide new information that would warrant a change in investment recommendation. The filing does not offer insights into the company's operational performance, strategic direction, or financial health that would influence a 'buy' or 'sell' decision. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the fundamental investment thesis.

Keywords

Marimed Inc., MRMD, Jon R. Levine, Insider Transaction, Form 4, Restricted Stock Units, Equity Compensation, Beneficial Ownership